Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

Trump is changing Medicare, mostly focusing on providers. But the biggest impact may come from tariffs and deporting ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Proposed experiment would allow states and Medicare drug plans to cover GLP-1 drugs like Ozempic and Wegovy for obesity, The ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

President Donald Trump is ratcheting up the pressure on major drugmakers to bring their US prices in line with the far lower ...

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

The GOP megabill now under Senate consideration threatens healthcare insurance for more than 1 million seniors who rely on Medicare.